Orset Caroline
Paris-Saclay Applied Economics (PSAE), AgroParistech, INRAe, Université Paris-Saclay, and Climate Economics Chair, Campus Agro Paris-Saclay, 22 place de l'Agronomie, 91120, Palaiseau, France.
Health Econ Rev. 2024 Oct 1;14(1):78. doi: 10.1186/s13561-024-00541-3.
The costs associated with respiratory illnesses in the French healthcare budget continue to rise. However, pharmaceutical companies and research centres are continuously developing new treatments. Consequently, accepting these treatments, which necessitates the acceptance of the mortality risk associated with their use, represents a significant economic and public health issue. Our study aims to assess this acceptance.
The data were obtained from an online questionnaire completed by 315 respondents located in France during June and July 2019. The standard gamble method was employed to ascertain the acceptability of risk. This method quantifies the 'disutility' of a health state by evaluating the extent to which an individual is willing to accept a specific mortality risk in exchange for avoiding the state.
The study demonstrated that individuals, irrespective of their personal characteristics, were willing to accept a treatment with an average mortality risk of less than 19%. The findings revealed discrepancies between individuals' perceptions of mortality and actual risks.
In France, it is incumbent upon public decision-makers and research centres to ensure that treatment-related mortality rates remain below 19% so that patients readily accept treatment, irrespective of their personal characteristics. In addition, they should provide further information on the risks associated with treating respiratory diseases to avoid a discrepancy between the mortality risks perceived by individuals and the actual risks.
法国医疗保健预算中与呼吸系统疾病相关的成本持续上升。然而，制药公司和研究中心不断研发新的治疗方法。因此，接受这些治疗（这需要接受与使用它们相关的死亡风险）是一个重大的经济和公共卫生问题。我们的研究旨在评估这种接受程度。
数据来自于2019年6月和7月期间法国315名受访者填写的在线问卷。采用标准博弈法确定风险的可接受性。该方法通过评估个体为避免某种健康状态而愿意接受特定死亡风险的程度来量化该健康状态的“负效用”。
研究表明，无论个人特征如何，个体都愿意接受平均死亡风险低于19%的治疗。研究结果揭示了个体对死亡的认知与实际风险之间的差异。
在法国，公共决策者和研究中心有责任确保与治疗相关的死亡率保持在19%以下，以便患者无论个人特征如何都能欣然接受治疗。此外，他们应提供有关治疗呼吸系统疾病相关风险的更多信息，以避免个体认知的死亡风险与实际风险之间出现差异。
